# Glycomine: Developing therapies for critical unmet orphan diseases of glycosylation

> We are developing a PMM2\-CDG substrate replacement therapy\. GLM101 is a mannose\-1 phosphate treatment\.

Generated by Yoast SEO v28.1, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Home](https://www.glycomine.com/)
- [GLM101](https://www.glycomine.com/glm101/)
- [News](https://www.glycomine.com/news/)
- [PMM2\-CDG](https://www.glycomine.com/pmm2-cdg/)
- [Careers](https://www.glycomine.com/careers/)

## News
- [Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2\-CDG](https://www.glycomine.com/glycomine-completes-enrollment-in-global-phase-2b-polar-study-of-glm101-for-the-treatment-of-pmm2-cdg/)
- [Glycomine Initiates Dosing in a Global, Randomized, Placebo\-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2\-CDG](https://www.glycomine.com/glycomine-initiates-dosing-in-a-global-randomized-placebo-controlled-phase-2b-study-of-glm101-for-the-treatment-of-pmm2-cdg/)

## Optional
- [Sitemap index](https://www.glycomine.com/sitemap_index.xml)